EyePoint Sues Ocular Therapeutix for Defamation Over DURAVYU™ Product Claims
EYPT has more than doubled off its 52-week low of $3.91.
Summary
EyePoint, Inc. has filed a lawsuit against Ocular Therapeutix, Inc., alleging defamation and commercial disparagement related to its lead product candidate, DURAVYU™.
Key Events · Legal and Risk Events · EYPT
-
Initiates Lawsuit Against Competitor
EyePoint, Inc. filed a complaint against Ocular Therapeutix, Inc. in the Middlesex County Superior Court for the Commonwealth of Massachusetts.
-
Alleges Defamation and Disparagement
The complaint alleges Ocular Therapeutix disseminated false or misleading representations of fact concerning EyePoint's lead product candidate, DURAVYU™ (vorolanib intravitreal insert), and its clinical results.
-
Seeks Injunctive Relief and Damages
EyePoint is seeking injunctive relief to prevent further dissemination of false statements, a public retraction, monetary damages, and attorneys' fees and costs.
Analysis · EYPT · Industrial Applications And Services
This lawsuit indicates a significant competitive dispute concerning EyePoint's lead product candidate, DURAVYU™. The company is taking aggressive legal action to protect its product's reputation and market position against alleged false or misleading representations by a competitor. While the outcome is uncertain, the initiation of such a suit highlights a material risk or opportunity related to the product's commercial success and could involve substantial legal costs or potential damages.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 29.5% of the 1672 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.22%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EYPT was trading at $13.23 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $3.91 to $19.11. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.